*Refresh the page if the below document does not appear.
Delhi HC rules in Novartis' favour on its divisional
patent application for a dry eye disease drug
Delhi High Court has overturned a Patent Office decision to reject Novartis AG’s application for a patent on a composition for the treatment of dry eye disease, and remanded the case back for further consideration of the divisional application’s merits.
Curatio to be acquired by Torrent Pharma
Torrent Pharmaceuticals,based in Ahmedabad, plans to purchase skincare product manufacturer Curatio Healthcare. Those with knowledge of the situation stated that the deal will value Curatio at $2,100 crore.
Formoterol Fumarate inhalation solution from
Lupin receives USFDA approval
Lupin announced on Wednesday that USFDA had given its formoterol fumarate inhalation solution, used to treat the signs and symptoms of chronic obstructive pulmonary disease approval.
NPPA panel denies Intas' request for waiver of
DPCO's requirements for clozapine ER capsules
National Pharmaceutical Pricing Authority’s expert panel has denied Intas Pharmaceuticals Ltd. ‘s request for an exemption from the requirements of the Drug Price Control Order 2013 for different strengths of its formulation of clozapine extended release (ER) capsules.
Pfizer outbid Johnson & Johnson in competing
for Global Blood Therapeutics
Pfizer had to battle Johnson & Johnson before deciding on a $5.4 billion price tag for Global Blood Therapeutics. J&J initiated the negotiations by proactively approaching GBT with a buyout offer before Pfizer entered the picture.
Indian vaccine producers overtake MNCs in
market share
For the first time, perhaps, indigenously manufactured vaccines have begun to take market share from MNCs in certain diseases, even as the Rs 3,000 crore private market fell by 15% month on month in June, one of the steepest such drops in recent years.
AstraZeneca's Soriot warns new drug price
law in US will stifle innovation
CEO of AstraZeneca expressed concern about
new legislation in the United States that would
cap drug prices and limit companies’ ability to
recover their investments in the development
of new drugs.